Industry News
Pharmaceutical Industry News
In its fifth year, the annual…
In its fifth year, the annual Hologic Global Women’s Health Index found only minimal improvements in preventive screening rates from the first report, and no change at all in an overall analysis of women’s health
Amid the U.S.’ war with Iran,…
Amid the U.S.' war with Iran, generic exports, drugs for clinical trials and local shipments of biologics that rely on cold chains in the region are likely to face increasing pressure if the conflict persists,
The company evaluated MC4R agonist…
The company evaluated MC4R agonist Imcivree across four genetic-driven obesity subgroups, with the treatment missing the primary BMI endpoint in each substudy.
Moderna CEO Stéphane Bancel’s…
Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable in 2025 despite the company’s revenue miss. Following a major cost-cutting initiative, the CEO’s pay package was bolstered by a $4.3 million cash bonus, the highest
A federal judge in Boston blocked…
A federal judge in Boston blocked significant parts of the HHS' vaccination agenda and effectively stopped an upcoming vaccines advisory panel from meeting later this week as originally scheduled.
While BioMarin has been focusing…
While BioMarin has been focusing heavily on its CNP analogue, Voxzogo, to write the next chapter of the company’s growth story, a change in its clinical development plans introduces further uncertainty into the company’s calculus.
Amgen’s Amjevita, Aimovig and…
Amgen’s Amjevita, Aimovig and Repatha—plus GSK's Ellipta inhalers and its Relenza—became available through the government drug platform on Monday.
Idorsia is gearing up for another…
Idorsia is gearing up for another CEO change with the news that Srishti Gupta, M.D., is leaving the company. As the company commences its search for a new CEO, board chair Jean-Paul Clozel, M.D., is
With positive results from a phase…
With positive results from a phase 3 trial of Ebglyss, Eli Lilly is set up to make the IL-13 inhibitor available to a younger group of patients with atopic dermatitis.
Johnson & Johnson is suing a…
Johnson & Johnson is suing a former oncology medical affairs employee who is now “employed by” Summit Therapeutics, alleging a massive and “malicious” stealing of trade secrets.
Kerendia, also known as…
Kerendia, also known as finerenone, met the mark in Bayer’s late-stage Find-CKD study in adult patients with chronic kidney disease (CKD) who don’t have diabetes, allowing the study to hit its primary endpoint. The drug
Cuando los medicamentos para perder peso no funcionan
Fármacos como Wegovy y Zepbound han sido aclamados como tratamientos milagrosos. Pero una de cada 10 personas es lo que los científicos llaman “no respondedores”.
The CEO’s 2025 pay was a sizeable…
The CEO's 2025 pay was a sizeable bump over the $24.6 million he collected in 2024, making for his second largest pay package since taking the helm in 2019.
GSK has secured an FDA expansion…
GSK has secured an FDA expansion for its respiratory syncytial virus vaccine, Arexvy, for adults ages 18 to 49 who are at increased risk of lower respiratory tract disease caused by the virus. The green
From its 17-year development cycle…
From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. And, for the twice-yearly pre-exposure prophylaxis medication—which Gilead Sciences has positioned as a key tool in the fight
Simtra BioPharma Solutions was…
Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the CDMO’s production plant in Halle, Germany.
The FDA has rejected Hyloris…
The FDA has rejected Hyloris Pharmaceuticals' antiviral valacyclovir, an oral suspension for infections caused by herpes simplex and varicella-zoster viruses becasue of manufacturing problems.
When Weight-Loss Drugs Don’t Work
Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call “non-responders.”
Eli Lilly is making investments in…
Eli Lilly is making investments in China, Japan and South Korea. Pfizer has broken into obesity thanks to a Chinese nod won by its local partner Sciwind Biosciences. Astellas' CEO attributed a better-than-expected reimbursement price
While much of the company’s…
While much of the company’s recent focus has remained on beefing up its U.S. infrastructure, Eli Lilly has for the second time this week made moves to raise capacity for its medicines overseas, and once